The future of regenerative medicine lies in understanding cellular communication and its role in tissue regeneration. Opublu Biologics advances this field through exosome technologies and mesenchymal stem cell (MSC) platforms, bridging scientific innovation from OEM manufacturing to clinical translation through strategic partnerships and proprietary intellectual property.